Zhou, Jun

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer

Cited by 593

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013) · Clinical Cancer Research

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 485

Emerging mRNA technologies: delivery strategies and biomedical applications

Xiao, Y., Tang, Z., Huang, X., Chen, W., Zhou, J., Liu, H., Liu, C., Kong, N., & Tao, W. (2022) · Chemical Society Reviews

RNA Interference and Gene DeliveryRNA and protein synthesis mechanisms

Cited by 255

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Subrahmanyam, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L. M., Maecker, H. T., & Hodi, F. S. (2018) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 190

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer

Cited by 164